Antagonist HIV-1 Gag peptides induce structural changes in HLA B8

Area of Science:

• Immunology
• Structural Biology
• Molecular Medicine

Background:

• Cytotoxic T-lymphocyte (CTL) recognition of viral antigens presented by HLA class I molecules is crucial for cellular immunity.
• Altered peptide ligands (APLs) are known to antagonize CTL recognition, potentially inhibiting the immune response against infected cells.
• Naturally occurring variants of the HIV-1 P17 epitope presented by HLA-B8 act as T-cell receptor (TCR) antagonists.

Purpose of the Study:

• To characterize the interactions between CTL clones/lines and variants of the HIV-1 P17 (aa 24-31) epitope.
• To determine the high-resolution crystal structures of APLs in complex with HLA-B8.
• To elucidate how APLs alter the TCR binding surface, affecting CTL recognition.

Main Methods:

• Characterization of CTL clones and a CTL line responses to P17 variants.
• High-resolution crystal structure determination of four APLs complexed with HLA-B8.
• Analysis of structural changes in peptide shape, chemistry, and flexibility at the TCR binding interface.

Main Results:

• Variant peptides induce changes in the TCR recognition surface through direct peptide contributions, transmitted effects, and induced framework alterations.
• The first two mechanisms often result in TCR antagonism.
• Induced effects on the peptide binding groove framework have profound impacts on TCR recognition.

Conclusions:

• Structural insights into APL-HLA-B8 complexes explain varied CTL responses to viral epitope variants.
• Understanding these structural mechanisms is key to designing APLs for modulating T-cell mediated immunity.
• The study highlights the complex interplay between peptide structure, HLA presentation, and TCR recognition in immune responses.